Daniel joins Charm Therapeutics from Ridgeline Discovery, where he helped build the next generation of innovative biotechs focusing on cellular therapy, large molecules, and small molecules.
Prior to his work at Ridgeline he was a Group Leader in the Oncology DTA at Roche as well as holding an Oncology early discovery position at GlaxoSmithKline in the USA.
Daniel obtained his Ph.D. from Weill Cornell Graduate School of Medical Sciences while working at Memorial Sloan Kettering in a collaboration with Agios Pharmaceuticals.
